HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BASF SEEKS FDA AUTHORIZATION TO MARKET PEG-25 PABA

This article was originally published in The Rose Sheet

Executive Summary

BASF SEEKS FDA AUTHORIZATION TO MARKET PEG-25 PABA pending the completion of the OTC sunscreen monograph review process. In a Feb. 4 letter, the company's attorney, Kathleen Sanzo from the Washington, D.C. law firm Morgan, Lewis & Bockius requested that FDA "state it is appropriate to include PEG-25 PABA in the OTC monograph review process and that...BASF and any similarly situated manufacturers are authorized to market their products pending completion by FDA of the OTC monograph review process for sunscreens."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

RS000135

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel